Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 4Phase 4 1Phase 1 1

Status

Completed 5Withdrawn 2

Sponsor Class

INDUSTRY 7OTHER 5FED 1

Study Type

Interventional 7

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

Certolizumab Pegol 5Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Crohn Disease × Clear all
NCT02499783 2019-01-04

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

AbbVie

Phase 3 Completed
205 enrolled 39 charts

Crohn Disease

NCT00552058 2018-08-09

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

UCB Pharma

Phase 3 Completed
439 enrolled 25 charts

Crohn Disease

NCT00333788 2018-08-07

Welcome2

UCB Pharma

Phase 3 Completed
233 enrolled 31 charts

Crohn Disease

NCT01369329 2016-12-07

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Janssen Research & Development, LLC

Phase 3 Completed
769 enrolled 13 charts

Colitis, Crohn Disease, Inflammatory Bowel Diseases

NCT00354367 2012-05-28

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

UCB Pharma

Phase 3 Withdrawn

Crohn Disease, Fistula

NCT00358683 2012-05-28

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

UCB Pharma

Phase 3 Withdrawn

Crohn Disease

NCT00297648 2011-08-31

MUSIC

UCB Pharma

Phase 3 Completed
89 enrolled 43 charts

Crohn Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡